Pre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 29; p. viii400
Main Authors	Hale, D.F., Mittendorf, E.A., Brown, T.A., Clifton, G.T., Vreeland, T.J., Myers, J., Peace, K., Jackson, D., Greene, J., Holmes, J., Peoples, G.E.
Format	Journal Article
Language	English
Published	England Elsevier Ltd 01.10.2018
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534 1569-8041
DOI:	10.1093/annonc/mdy288.001